共 121 条
[1]
Lipton RB(2017)Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 Lancet 390 1211-1259
[2]
Bigal ME(2019)Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 Lancet Neurol 18 459-480
[3]
Diamond M(2007)Migraine prevalence, disease burden, and the need for preventive therapy Neurology. 68 343-349
[4]
Freitag F(2013)Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the second international burden of migraine study (IBMS-II) Headache. 53 644-655
[5]
Reed ML(2017)Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: a retrospective claims analysis Cephalalgia. 37 470-485
[6]
Stewart WF(2017)A real-world analysis of migraine: a cross-sectional study of disease burden and treatment patterns Headache. 57 1532-1544
[7]
Blumenfeld AM(2020)Pharmacologic characterization of ALD403, a potent neutralizing humanized monoclonal antibody against the calcitonin gene-related peptide J Pharmacol Exp Ther 374 93-103
[8]
Bloudek LM(2018)A phase-by-phase review of migraine pathophysiology Headache. 58 4-16
[9]
Becker WJ(2018)CGRP as the target of new migraine therapies — successful translation from bench to clinic Nat Rev Neurol 14 338-350
[10]
Buse DC(2017)Spotlight on anti-CGRP monoclonal antibodies in migraine: the clinical evidence to date Clin Pharmacol Drug Dev 6 534-547